Drugs / antiplatelet thrombolysin
last change Dec 2017 re-read 2 minutes ago

antiplatelet thrombolysin

Developed for
coronary artery disorder
Investigated by
National Natural Science Foundation of China · The First Affiliated Hospital with Nanjing Medical University

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03078257 Jan 2016 → Nov 2017 coronary artery disorder The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as antiplatelet thrombolysin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078257
Action Inhibit “GP Ib receptor antagonist” NCT03078257
Route Other “through PV” NCT03078257